Compare Silvercorp Metals Inc. Common Shares (SVM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Silvercorp Metals Inc. Common Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Silvercorp Metals Inc. Common Shares trades at $9.43 (market cap $2.09B), while Vertex Pharmaceuticals Incorporated trades at $513.46 (market cap $126.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 60.5× Silvercorp Metals Inc. Common Shares's market cap, and Silvercorp Metals Inc. Common Shares pays a 0.27% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Silvercorp Metals Inc. Common Shares for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SVM | VRTX | |
|---|---|---|
Market Cap | $2.09B | $126.35B |
Volume | 3,359,240 | 2,089,984 |
Sector | Basic Materials | Health |
52-Week High | $15.71 | $557.96 |
52-Week Low | $6.09 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $1.82B | $120.48B |
Dividend Yield | 0.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Vertex Pharmaceuticals (VRTX) trades at $485.22, down 4.3% amid bearish technical signals, though fundamentals remain strong with $12B revenue and 35% net margins. Recent positive Phase 2b data for kidney drug inaxaplin and dominant cystic fibrosis position support growth. Analyst consensus is bullish with $573.50 price target, but earnings misses in two of last three quarters highlight execution risks.
The outlook balances robust profitability and pipeline progress against competitive pressures and regulatory hurdles. Upside potential exists if new therapies gain approval, but volatility may persist near-term. Investors should weigh high valuations against the company's market leadership and expanding gene therapy portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Silvercorp Metals Inc. Common Shares
Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
